HYPERION DEFI INC

HYPERION DEFI INC, a Nasdaq‑listed New York biopharma focusing on eye disease drugs, shows a volatile stock with a negative P/E yet potential growth in ophthalmology.

Hyperion DeFi launches its Institutional Volatility Income Vault on the Rysk Protocol, offering institutional investors a new, robust solution to manage market volatility.

Hyperion DeFi Inc (HDF) faces steep volatility and negative earnings. Explore the latest stock performance, airdrop news, and investor cautions for a clear picture of its risky future.

Hyperion DeFi Inc. is pioneering eye‑disease treatments—from glaucoma to dry eye—while navigating biotech volatility, aiming to deliver innovative ophthalmology therapies that improve patient outcomes.